Comparative Pharmacology
Head-to-head clinical analysis: CORMAX versus SERNIVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORMAX versus SERNIVO.
CORMAX vs SERNIVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive effects. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release.
SERNIVO (clobetasol propionate) is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects through induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
2.5 mg orally twice daily; maximum 10 mg/day.
Apply a thin layer to affected area twice daily for up to 2 weeks.
None Documented
None Documented
Terminal elimination half-life: 3.5 hours (range 2.5-4.5 h); clinical context: dosing every 4-6 hours to maintain therapeutic levels
Approximately 3 hours (parent drug); clinical duration extended via formulation.
Renal: 90% unchanged; minor biliary/fecal: <5%
Primarily renal excretion of inactive metabolites; <5% unchanged. Minor biliary/fecal elimination.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid